|
|
|
|
|
 |
Company Fact Sheet
|
|
| |
|
Company Fact Sheet
>> A printer-friendly PDF version of this information is available for download.
Company Focus
BioMimetic Therapeutics Inc.'s mission is to be a leader in the development and commercialization of drug-device combination products that speed the healing of orthopedic, spine and sports injuries. The Company is developing biologically enhanced therapies to improve the treatment options and quality of life for millions of patients suffering injuries to bones, cartilage (joints), ligaments and tendons.
President and Chief Executive Officer
Samuel Lynch, D.M.D., D.M.Sc. Dr. Lynch is the president and CEO.
Chairman of the Board
Larry W. Papasan. Mr. Papasan has been the chairman of the board since August 2005.
Founded
The Company closed its Series A funding and was officially incorporated in May of 2001.
Stock Listing
NASDAQ: BMTI
Date of IPO
May 12, 2006
Number of Shares Outstanding
18,581,855 [as of August 7, 2008]
Number of Employees
Approximately 95
Area of Expertise
BioMimetic Therapeutics believes it is uniquely positioned to develop a variety of enhanced medical devices through the combination of existing medical devices and a biologically active growth factor (rhPDGF) that will stimulate tissue regeneration and repair, thereby providing faster healing and a better functional outcome for the patient. Further, BioMimetic believes that this strategy positions the Company to open new musculoskeletal product segments that address underserved or unmet clinical needs, particularly in advancing the treatment of fractures and injuries of cartilage, ligaments, and tendons.
Key Products and Product Candidates - Growth-factor Enhanced Matrix GEM 21S :: The Company's first product candidate, GEM 21S , has been approved by the FDA for the treatment of bone loss associated with advanced periodontal disease. BioMimetic's dental business is now owned by Luitpold Pharmaceuticals, Inc.
- Augment™ Bone Graft :: BioMimetic is developing Augment Bone Graft for use in open fracture reduction, or fractures requiring surgery. Augment Bone Graft is designed to be placed directly into an open surgical site for the stimulation of bone regeneration. Augment Bone Graft is similar to GEM 21S in that it combines a particulate β–TCP with rhPDGF-BB.
- Augment™ Injectable Bone Graft Putty :: BioMimetic is developing this injectable product for the treatment of fractures not requiring surgery and for prophylactic bone augmentation. The Augment Injectable Bone Graft product combines rhPDGF-BB with an injectable bone matrix.
- Cartilage, Ligament and Tendon Product Candidates :: BioMimetic is using its proprietary technology to develop products addressing unmet medical needs in sports injury, initially targeting cartilage, ligament and tendon repair and regeneration.
Important Dates - 1985 :: Dr. Samuel Lynch and colleagues begin developing the technology for the rhPDGF protein, found to be one of the principal wound healing stimulators in the body
- May 2001 :: The Company closes its Series A funding and is officially incorporated; BMTI signs agreements with Chiron Corporation, ZymoGenetics, Inc. and Harvard Medical School
- August 2003 :: BioMimetic and Orthovita enter into a supply agreement for resorbable beta-tricalcium phosphate scaffold
- December 2003 :: The Company signs a strategic alliance with Luitpold Pharmaceuticals to distribute GEM 21S
- July 2004 :: The Company executes a commercial manufacturing agreement with Chiron Corporation for the large-scale manufacture of purified rhPDGF
- November 2004 :: BioMimetic closes a Series C round of financing raising $25.7 million
- July 2005 :: The Company relocates its headquarters to the Cool Springs Life Sciences Center just south of Nashville in Franklin, Tennessee
- November 2005 :: The Company's first product, GEM 21S, is approved by the FDA for the treatment of periodontally-related bone defects
- March 2006 :: BioMimetic announces that clinical trials of Augment Bone Graft have been initiated in the United States, Canada and Sweden
- May 2006 :: BioMimetic closes its initial public offering (IPO) and begins trading on the NASDAQ Market under the ticker symbol BMTI
- July 2006 :: Augment Bone Graft enters pivotal (registration) trials for foot and ankle fusion indications in Canada
- February 2007 :: BioMimetic completes public offering of approximately 3.25 million shares of common stock including the sale of all over-allotment shares
- April 2007 :: BioMimetic initiates patient enrollment in U.S. pivotal trial for Augment Bone Graft for the treatment of foot and ankle fusions
- January 2008 :: BioMimetic closes on sale of remaining dental business, including the manufacturing rights of GEM 21S, to Luitpold Pharmaceuticals
Corporate Headquarters
389 Nichol Mill Lane, Franklin TN 37067
615-844-1280
Web Site Address
www.biomimetics.com
Company Email Address
info@biomimetics.com |
|
|
| |
 |
|
|
| |
| |
|
|
|
|
|
